Baskhanbiopharma (XKRX:354390) Debt-to-Equity : 0.01 (As of Dec. 2023)

View and export this data going back to 2022. Start your Free Trial

What is Baskhanbiopharma Debt-to-Equity?

Baskhanbiopharma's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was ₩159 Mil. Baskhanbiopharma's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was ₩9 Mil. Baskhanbiopharma's Total Stockholders Equity for the quarter that ended in Dec. 2023 was ₩27,415 Mil. Baskhanbiopharma's debt to equity for the quarter that ended in Dec. 2023 was 0.01.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Baskhanbiopharma's Debt-to-Equity or its related term are showing as below:

XKRX:354390' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.01 Med: 0.02 Max: 0.13
Current: 0.01

During the past 4 years, the highest Debt-to-Equity Ratio of Baskhanbiopharma was 0.13. The lowest was 0.01. And the median was 0.02.

XKRX:354390's Debt-to-Equity is ranked better than
99.88% of 845 companies
in the Drug Manufacturers industry
Industry Median: 0.3 vs XKRX:354390: 0.01

Baskhanbiopharma Debt-to-Equity Historical Data

The historical data trend for Baskhanbiopharma's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Baskhanbiopharma Debt-to-Equity Chart

Baskhanbiopharma Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Debt-to-Equity

0.13

0.02

0.01

Baskhanbiopharma Semi-Annual Data
	Dec20	Dec21	Dec22	Dec23
Debt-to-Equity	0.13	0.02	0.02	0.01

Competitive Comparison of Baskhanbiopharma's Debt-to-Equity

For the Drug Manufacturers - Specialty & Generic subindustry, Baskhanbiopharma's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Baskhanbiopharma's Debt-to-Equity Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Baskhanbiopharma's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Baskhanbiopharma's Debt-to-Equity falls into.

Baskhanbiopharma Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Baskhanbiopharma's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(159.405	+	8.833)	/	27414.567
	=	0.01

Baskhanbiopharma's Debt to Equity Ratio for the quarter that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(159.405	+	8.833)	/	27414.567
	=	0.01

Baskhanbiopharma (XKRX:354390) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Baskhanbiopharma Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Baskhanbiopharma's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Baskhanbiopharma (XKRX:354390) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Baskhanbiopharma Inc (XKRX:354390) » Definitions » Debt-to-Equity

Traded in Other Exchanges

N/A

Address

354 Wondang-ro, Wongok-myeon, Anseong-si, Gyeonggi-do, KOR

Website

https://www.baskhanbio.com

Baskhanbiopharma Inc manufactures and distributes prescription drugs, over the counter drugs, medical devices and other related products.

Baskhanbiopharma (XKRX:354390) Headlines

No Headlines